Literature DB >> 35069822

Synergistic effect of Bruton's tyrosine kinase and TNF-α in the regulation of rheumatoid arthritis and underlying mechanisms.

Jinwan Du1.   

Abstract

The presence of Bruton's tyrosine kinase (BTK) in macrophages has been recommended as a promising therapeutic target for rheumatoid arthritis (RA). In addition, activated macrophages in the inflamed joints of patients with RA can also produce a plethora of cytokines, such as TNF-α. The aim of the present study was to investigate the potential role of BTK and TNF-α in the regulation of RA. The results demonstrated that higher levels of BTK and TNF-α were observed in macrophages in inflamed RA joints compared with those in normal joint tissues. Subsequently, the role of BTK and TNF-α in the regulation of cellular process in inflammatory macrophages was analyzed. It was demonstrated that aberrant expression of BTK and TNF-α in inflammatory macrophages can lead to higher cell proliferation rates. Once the expression of BTK or TNF-α was restricted by using short interfering (si)RNAs (siBTK or siTNF-α), the activity of inflammatory macrophages was significantly downregulated. Of note, when the expression of BTK and TNF-α was simultaneously decreased, the proliferation rate of inflammatory macrophages was inhibited to the greatest extent. Subsequently, the underlying mechanisms through which BTK and TNF-α can regulate RA were investigated. The results demonstrated that BTK mainly regulated the ERK/JNK pathway, while TNF-α mainly affected the inactive rhomboid protein 2/B-cell-activating factor pathway. Finally, animal experiments demonstrated that simultaneous silencing of both BTK and TNF-α can significantly alleviate the symptoms associated with RA.
Copyright © 2020, Spandidos Publications.

Entities:  

Keywords:  Bruton's tyrosine kinase; ERK/JNK pathway; TNF-α; inactive rhomboid protein 2/TNF-α/B-cell-activating factor pathway; rheumatoid arthritis

Year:  2021        PMID: 35069822      PMCID: PMC8756421          DOI: 10.3892/etm.2021.11064

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  38 in total

Review 1.  The role of BAFF and APRIL in rheumatoid arthritis.

Authors:  Arezoo G Shabgah; Zhaleh Shariati-Sarabi; Jalil Tavakkol-Afshari; Mojgan Mohammadi
Journal:  J Cell Physiol       Date:  2019-04-02       Impact factor: 6.384

Review 2.  Tyrosine kinase inhibitors for the treatment of rheumatoid arthritis: phase I to Ⅱ clinical trials.

Authors:  Jing Wu; Zhaohua Zhu; Qinghong Yu; Changhai Ding
Journal:  Expert Opin Investig Drugs       Date:  2019-11-20       Impact factor: 6.206

3.  Essential role of MAPK phosphatase-1 in the negative control of innate immune responses.

Authors:  Konstantin V Salojin; Iris B Owusu; Karen A Millerchip; Mark Potter; Ken A Platt; Tamas Oravecz
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

4.  Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis.

Authors:  G Schett; M Tohidast-Akrad; J S Smolen; B J Schmid; C W Steiner; P Bitzan; P Zenz; K Redlich; Q Xu; G Steiner
Journal:  Arthritis Rheum       Date:  2000-11

Review 5.  Investigational Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis.

Authors:  Peter Norman
Journal:  Expert Opin Investig Drugs       Date:  2016-05-09       Impact factor: 6.206

6.  The Role of Macrophages in the Response to TNF Inhibition in Experimental Arthritis.

Authors:  Qi-Quan Huang; Robert Birkett; Renee Doyle; Bo Shi; Elyssa L Roberts; Qinwen Mao; Richard M Pope
Journal:  J Immunol       Date:  2017-11-17       Impact factor: 5.422

Review 7.  Monocytes in rheumatoid arthritis: Circulating precursors of macrophages and osteoclasts and, their heterogeneity and plasticity role in RA pathogenesis.

Authors:  Amit Kumar Rana; Yang Li; Qiujie Dang; Fan Yang
Journal:  Int Immunopharmacol       Date:  2018-10-23       Impact factor: 4.932

Review 8.  Managing macrophages in rheumatoid arthritis by reform or removal.

Authors:  Jun Li; Hui-Chen Hsu; John D Mountz
Journal:  Curr Rheumatol Rep       Date:  2012-10       Impact factor: 4.592

9.  The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells.

Authors:  Betty Y Chang; Min Mei Huang; Michelle Francesco; Jun Chen; Jeremy Sokolove; Padmaja Magadala; William H Robinson; Joseph J Buggy
Journal:  Arthritis Res Ther       Date:  2011-07-13       Impact factor: 5.156

10.  B-cell phenotype and IgD-CD27- memory B cells are affected by TNF-inhibitors and tocilizumab treatment in rheumatoid arthritis.

Authors:  Rita A Moura; Cláudia Quaresma; Ana R Vieira; Maria J Gonçalves; Joaquim Polido-Pereira; Vasco C Romão; Nádia Martins; Helena Canhão; João E Fonseca
Journal:  PLoS One       Date:  2017-09-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.